Pietro Melchiorri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pietro Melchiorri has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Emilio Panerai
Dipartimento di Scienze Farmacologiche e Biomolecolari, University of Milan, Via Vanvitelli 32, 20129 Milano, Italy
1 shared publication - Donatella Lattuada
University of Study
1 shared publication - Elisa Giannini
2"V. Erspamer" Department of Human Physiology and Pharmacology, "La Sapienza" University, Piazza Aldo Moro, Rome, Italy
1 shared publication - Hui Tian
Department of Thoracic Surgery, Qi Lu Hospital, Shandong University, Jinan, Shandong Province, China
1 shared publication - Lucia Negri
Department of Physiology and Pharmacology "Vittorio Erspamer," Sapienza University of Rome, Rome, Italy
1 shared publication - Paola Sacerdote
University of Milan
1 shared publication
Latest Publications
- Open Access
- 28 October 2008
- Published by Springer Nature in BMC Immunology
- Vol. 9 (1) , 60
The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1
Background: Bv8, prokineticin-1, or endocrine gland-vascular endothelial growth factor, and prokineticin-2 are recently isolated peptide agonists of two G protein-coupled receptors, prokineticin receptor-1 (PROKR 1) and PROKR 2, and have been described as affecting a number of myeloid cell functions. We evaluated the impact of Bv8 on lymphoid cells by investigating its ability to modulate T cell cytokine balance in mouse.Results: The production of T-helper1 cytokines (IL-2, IFN-γ and IL-1β), the T-helper 2 cytokine IL-4, and the anti-inflammatory cytokine IL-10 by mouse splenocytes was evaluated after polyclonal stimulation or immunisation with the keyhole limpet hemocyanin protein antigen by measuring cytokine levels. When addedin vitroto Con-A-stimulated splenocytes, Bv8 significantly increased IL-1β and decreased IL-4 and IL-10; IL-2 and IFN-γ were not affected. Similar results were obtained when Bv8 was administeredin vivo. In KLH-immunised mice, splenocytes restimulatedin vitrowith KLH and Bv8 produced significantly smaller amounts of IL-4 and IL-10. KLH-induced IL-10 and IL-4 production was also significantly blunted in animals administered Bv8in vivoat the time of KLH immunisation or two weeks later. The Bv8-induced effects were lost in mice lacking the PROKR 1 gene, thus indicating that PROKR 1 is the receptor involved in the modulation of cytokines.Conclusion: These findings indicate that Bv8/prokineticin-1 is a novel modulator of lymphoid functions, and may be a suitable target for new immunopharmacological strategies.
- 28 October 2008
- Published by Springer Nature in BMC Immunology
- Vol. 9 (1) , 60
Open AccessThe prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1
Background: Bv8, prokineticin-1, or endocrine gland-vascular endothelial growth factor, and prokineticin-2 are recently isolated peptide agonists of two G protein-coupled receptors, prokineticin receptor-1 (PROKR 1) and PROKR 2, and have been described as affecting a number of myeloid cell functions. We evaluated the impact of Bv8 on lymphoid cells by investigating its ability to modulate T cell cytokine balance in mouse.Results: The production of T-helper1 cytokines (IL-2, IFN-γ and IL-1β), the T-helper 2 cytokine IL-4, and the anti-inflammatory cytokine IL-10 by mouse splenocytes was evaluated after polyclonal stimulation or immunisation with the keyhole limpet hemocyanin protein antigen by measuring cytokine levels. When addedin vitroto Con-A-stimulated splenocytes, Bv8 significantly increased IL-1β and decreased IL-4 and IL-10; IL-2 and IFN-γ were not affected. Similar results were obtained when Bv8 was administeredin vivo. In KLH-immunised mice, splenocytes restimulatedin vitrowith KLH and Bv8 produced significantly smaller amounts of IL-4 and IL-10. KLH-induced IL-10 and IL-4 production was also significantly blunted in animals administered Bv8in vivoat the time of KLH immunisation or two weeks later. The Bv8-induced effects were lost in mice lacking the PROKR 1 gene, thus indicating that PROKR 1 is the receptor involved in the modulation of cytokines.Conclusion: These findings indicate that Bv8/prokineticin-1 is a novel modulator of lymphoid functions, and may be a suitable target for new immunopharmacological strategies.